[Anesthetic management of a patient with hemophilia B during scoliosis surgery]

Masui. 2013 Oct;62(10):1241-4.
[Article in Japanese]

Abstract

Posterior spinal fusion for scoliosis was planned in a 14-year-old male patient with hemophilia B. Preoperative examination showed factor IX activity of 8.4% with no inhibitor development. A perioperative dosage schedule was prepared after examining the pharmacokinetics of recombinant coagulation factor IX in order to maintain levels of perioperative factor IX activity at < or = 80% for the first 6 days (days 0-6), and > or = 40% for days 7-14 postoperatively. The dose of recombinant coagulation factor IX was adjusted to maintain factor IX activity above 80%, while measuring coagulation activity every hour during the surgery. The patient showed a favorable course without hemorrhagic tendency. We could safely manage anesthesia without requiring allogeneic blood transfusion.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adolescent
  • Anesthesia, General / methods*
  • Factor IX / administration & dosage
  • Hemophilia B / complications*
  • Humans
  • Male
  • Recombinant Proteins / administration & dosage
  • Scoliosis / surgery*
  • Spinal Fusion

Substances

  • Recombinant Proteins
  • Factor IX